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Despite a few breakthroughs in therapy for advanced disease in the recent years, pancreatic ductal adenocarcinoma
continues to remain one of the most challenging human malignancies to treat. The overall prognosis for the majority of
patients with pancreatic cancer is rather dismal, and therefore, more effective treatment options are being desperately
sought. The practical goals of management are to improve the cure rates for patients with resectable disease, achieve a
higher conversion rate of locally advanced tumor into potentially resectable disease, and finally, prolong the overall
survival for those who develop metastatic disease. Our understanding of the complex genetic alterations, the implicated
molecular pathways, and the role of desmoplastic stroma in pancreatic cancer tumorigenesis has increased several folds
in the recent years. This has facilitated the development of novel therapeutic strategies against pancreatic cancer, some
of which are currently under evaluation in ongoing preclinical and clinical studies. This review will summarize the
existing treatment approaches for this devastating disease and also discuss the promising therapeutic approaches that
are currently in different stages of clinical development.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related mortality in the US for
both men and women [1]. In 2015 alone, it is estimated
that 48,960 new cases of pancreatic cancer will be diag-
nosed in the US and 40,560 patients will die of this
disease. As such, PDAC remains one of the most chal-
lenging malignancies with a dismal prognosis and lim-
ited therapeutic options. The 5-year survival rate for
pancreatic cancer (all stages combined) is around 7%,
which is the lowest among all different cancer sites. At
the time of initial pancreatic cancer diagnosis, approxi-
mately 9% of patients present with localized disease, 28%
have regional spread, and the remaining 53% of patients
already have distant spread of their disease. There has
been a very limited clinically meaningful improvement
in survival rates for this disease during the past two* Correspondence: sunw@upmc.edu
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unless otherwise stated.decades. The poor prognosis of PDAC is largely attributed
to delayed diagnosis due to nonspecific symptoms in the
early stages of the disease, biological aggressiveness lead-
ing to rapid metastases, lack of effective screening
methods, and resistance to radiation and chemotherapies.
It is now well established that PDAC is driven by al-
teration of multiple genes that regulate pathways and
processes in the tumor cells and the neighboring
microenvironment [2]. Despite our improved under-
standing of the molecular events underlying the multi-
step carcinogenesis of PDAC, the progress made
towards improving the survival rates of these patients
has been extremely slow. At present, multiple novel
treatment strategies targeted against PDAC are under
preclinical and clinical evaluation. This review will
summarize the existing treatment approaches for this
devastating disease and also discuss the promising
therapeutic strategies that are currently in the different
stages of clinical development.l. This is an Open Access article distributed under the terms of the Creative
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The known risk factors that increase the likelihood of
developing PDAC include cigarette smoking [3], alcohol
abuse [4], high fat diet [5], and certain trace elements
[6]. It is estimated that cigarette smoking doubles the
risk of developing PDAC and accounts for approxi-
mately 20%–25% of the cases [3]. Chronic pancreatitis is
also associated with an increased risk of PDAC, espe-
cially among smokers [7]. It has also been noted that the
majority of patients with PDAC develop diabetes melli-
tus which is usually diagnosed in the preceding 1–2
years or concomitant with the new cancer diagnosis [7].
It is not entirely clear whether diabetes is a predisposing
factor or a manifestation of PDAC itself. Obesity, which
predisposes to insulin resistance, might be a common
link between the two.
Approximately 5%–10% of patients with PDAC report
a history of pancreatic cancer diagnosis in their family
member [8]. The genetic syndromes such as familial
breast cancer (BRCA2, BRCA1, and PALB2), the Peutz-
Jeghers syndrome (LKB1/STK11), the familial atypical
multiple mole melanoma (FAMMM) syndrome (p16/
CDKN2A), hereditary pancreatitis (PRSS1), and the
lynch syndrome (MLH1, MSH2, MSH6, PMS2) are also
associated with an increased risk of developing PDAC
[8,9]. Thus, patients with a family history of pancreatic
cancer or these mutation carriers should undergo ap-
propriate screening, as per the guidelines provided by
the International Cancer of the Pancreas Screening
Consortium [10].
Genetics and molecular pathogenesis
Pancreatic cancer most commonly originates in the exo-
crine cells of the pancreas [11]. Among the exocrine tu-
mors, ‘ductal adenocarcinoma’ is the most frequently
encountered pathological subtype and accounts for more
than 90% of the cases. Initiation and development of
PDAC involve a series of specific genetic alterations
which promote growth and survival of aberrant precur-
sors, initiation of a desmoplastic reaction in the stroma,
and ultimately tissue invasion and metastases [12]. This
oncogenic process begins with transformation of normal
pancreatic duct epithelium into infiltrating cancer through
a series of histologically defined precursors called pancre-
atic intraepithelial neoplasia (PanIN)-1, -2, and -3 [11].
These morphological changes occur in conjunction with
several genetic alterations. Disease progression often in-
volves development of distant metastases, which occurs
late during the genetic evolution of pancreatic cancer [13].
Using genome sequencing, it has been determined that
after the initiation of tumorigenesis, an average of
11.7 years is required for the birth of parental, non-
metastatic founder pancreatic cancer clone, additional
6.8 years for the development of cancer cell subcloneswith metastatic potential, and an average of 2.7 years from
then until the patient’s death [13].
It is now well established that pancreatic cancer cells
contain one or more of the four primary genetic muta-
tions that drive pancreatic cancer tumorigenesis [14].
These include KRAS, p16/CDKN2A, TP53, and SMAD4
mutations. KRAS plays a critical role in regulating import-
ant cellular functions including cell survival, cell differen-
tiation, and proliferation [15]. Single point mutations in
codon 12, 13, 59, or 61 of exon 2 and exon 3 of the KRAS
oncogene lead to uncontrolled downstream signaling of
RAF/MEK/ERK, leading to enhanced tumor cell prolifera-
tion and survival. It has been shown that these activating
mutations in the KRAS are a necessary event for the initi-
ation of pancreatic cancer and are therefore commonly
found in the early precursor lesions (PanIN-1) [16,17].
With disease progression, the prevalence of oncogenic
KRAS mutation increases and is present in over 90% of
the tumors [17,18]. Inactivating mutation in the CDKN2A
tumor suppressor gene results in the loss of p16 protein
and thereby loss of regulation of the G1/S transition of the
cell cycle. It is also thought to be a relatively early event in
PDAC progression (PanIN-2 lesions) and is associated
with larger tumors and early metastasis [17,19]. TP53 is a
DNA checkpoint regulator in response to mutations from
reactive oxygen species as well as telomere shortening.
Abnormal TP53 gene allows cells to avoid DNA damage
control checkpoints and subsequently apoptotic signals
[20]. SMAD4 is a key component of the transforming
growth factor-β (TGF-β) receptor signaling pathway and
plays a role in activating transcription of cell cycle inhibi-
tory factors. Inactivation of TP53 and SMAD4 occur at a
later stage (PanIN-3) in pancreatic carcinogenesis [17].
A comprehensive genome analysis of 24 different hu-
man pancreatic cancers revealed an average of 63 gen-
etic alterations per cancer, the majority of which were
point mutations [2]. These mutations occur in several
primary oncogenes and tumor suppressor genes and
contribute to the genetic diversity of pancreatic cancer.
This, in turn, leads to tumor heterogeneity, instability,
and early metastasis. The genetic alterations associated
with pancreatic cancer can be classified into a set of 12
core cellular signaling pathways: apoptosis, control of
G1/S phase transition, sonic hedgehog (SHH) signaling,
KRAS signaling, TGF-β signaling, Wnt/Notch signaling,
DNA damage control, homophilic cell adhesion, integrin
signaling, JNK signaling, invasion, and small GTPase sig-
naling [2]. These pathways are responsible for some of
the key cellular functions such as intracellular signaling,
cell cycle regulation, metabolism, and DNA repair. Tar-
geting these pathways has now become the main focus
of drug development in pancreatic cancer.
A prominent histologic hallmark of PDAC is the presence
of a desmoplastic reaction which consists of extracellular
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neuronal cells, and collagen. This is mediated by para-
crine signals from the pancreatic cancer cells which re-
sults in the formation of a dense stroma in the tumor
microenvironment [21]. It is now established that the
signals that promote this stromal reaction originate
from the KRAS-mutant oncogene in the epithelium of
pancreatic cancer cells. SHH signaling also acts in a
paracrine fashion on the extracellular fibroblasts,
resulting in their growth and differentiation [22]. The
desmoplastic reaction not only acts as a mechanical
barrier to the effective delivery of chemotherapeutic
agents, it also provides an antiangiogenic and hypoxic
microenvironment in which the pancreatic cancer cells
like to grow and flourish.
Thus, it is now established beyond doubt that the wide
range of genetic alterations and the stromal reaction play
an important role in the initiation, progression, chemo-
therapeutic resistance, and recurrence of pancreatic
cancer.
Clinical management
Localized disease
The recommended treatment for patients presenting
with localized disease is surgery, since complete surgical
resection with negative margins offers the only hope for
cure in pancreatic cancer treatment [23]. Unfortunately,
only 9% of the pancreatic cancer patients present with
localized disease that is completely resectable at the time
of initial diagnosis [1]. Depending upon the size and the
location of the tumor, the operative procedure is either a
cephalic pancreaticoduodenectomy (Whipple proced-
ure), distal pancreatectomy, or total pancreatectomy
[24]. The success of surgical resection depends on fac-
tors such as extent of lymph node involvement, tumor
grade, tumor size, CA 19-9 levels, and the positivity of
resection margins. Even following complete surgical resec-
tion, the 5-year survival rates are low at approximately
20%, and the overall prognosis remains discouraging [23].
Thus, postoperative treatment in the form of adjuvant
chemotherapy [25] or chemoradiotherapy [26,27] is usually
administered and is often gemcitabine- or 5-fluorouracil
(5-FU)-based. The Charité Onkologie Clinical Studies in
Gastrointestinal Cancers-001 (CONKO-001) trial random-
ized 354 patients with localized PDAC to receive either ad-
juvant gemcitabine or undergo observation after curative
resection [28]. Gemcitabine arm was associated with a
significant improvement in disease-free survival (DFS;
13.4 months vs. 6.9 months; P < 0.001). The median
overall survival (OS) was however similar in the two
arms (22.1 months vs. 20.2 months; P = 0.06) and was
explained by the administration of gemcitabine to patients
in the observation arm after disease progression. The
European Study Group for Pancreatic Cancer (ESPAC)-3trial compared gemcitabine vs. 5-FU in the adjuvant treat-
ment of PDAC [25]. In this trial, 1,088 patients were ran-
domized to receive either 5-FU/Leucovorin (LV) or
gemcitabine. There was no difference in the median OS
(23 months vs. 23.6 months; P = 0.39), progression-free
survival (PFS; 14.1 months vs. 14.3 months; P = 0.53), and
the global quality of life (QoL) scores between the treat-
ment groups. In the Radiation Therapy Oncology Group
(RTOG)-9704 trial, 451 patients with resected PDAC re-
ceived either gemcitabine or 5-FU chemotherapy before
and after 5-FU-based chemoradiation [29]. Among pa-
tients with pancreatic head tumors, a statistically non-
significant improvement in median OS was seen in the
gemcitabine containing arm (20.5 months vs. 16.9 months;
P = 0.09). A phase III adjuvant trial (UNICANCER) com-
paring gemcitabine vs. modified FOLFIRINOX in surgi-
cally resected (R0 or R1) PDAC patients is currently
ongoing (NCT01526135). Another phase III RTOG-0848
trial is comparing adjuvant gemcitabine with or without
erlotinib in the first randomization and additional benefit
of chemoradiation in the second randomization for pa-
tients with localized PDAC who have undergone R0 or R1
surgical resection (NCT01013649).
Another potential strategy for the treatment of local-
ized pancreatic cancer is to administer chemotherapy in
the neoadjuvant setting, and this approach has also been
explored in multiple phase II clinical trials [30-34]. The
rationale for this approach includes early treatment of
micrometastatic disease, delivery of chemotherapy to an
undisturbed tumor, and biological assessment of tumor
aggressiveness [35]. An ongoing phase III study is com-
paring neoadjuvant gemcitabine/oxaliplatin combination
vs. upfront surgery, to be followed by adjuvant gemcita-
bine in patients with resectable PDAC (NCT01314027).
Locally advanced pancreatic cancer
Locally advanced pancreatic cancer (LAPC) is the tumor
that is confined locoregionally with some degree of in-
volvement of the nearby major vascular structures but
without any evidence of distant metastases. Approxi-
mately 30% of the patients are found to have locally ad-
vanced stage at the time of initial pancreatic cancer
diagnosis [1]. Patients are usually classified as having ei-
ther borderline-resectable or unresectable LAPC, de-
pending upon the relationship of the tumor with the
nearby vascular structures. Unfortunately, there are no
standard guidelines for the management of LAPC. This
is mainly due to the absence of a single standardized
definition of LPAC, which limits a fair comparison of
treatment strategies and results across the clinical trials.
The only potential way to achieve a cure in patients
with LAPC is by maximizing upfront systemic and local
therapy followed by a R0 surgical resection. For
borderline-resectable LAPC patients that are deemed
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the form of chemotherapy with or without radiation is
usually performed [36-39]. Such neoadjuvant therapies
have the potential to downstage borderline-resectable
disease and make R0 resection feasible. For initially
unresectable LAPC, neoadjuvant therapy should be of-
fered as a bridge to potentially curative resection.
Neoadjuvant therapy options include concurrent che-
moradiation, chemotherapy alone, and chemotherapy
followed by chemoradiation. A 1981 trial conducted by
the Gastrointestinal Tumor Study Group (GITSG) estab-
lished the superiority of combined 5-FU/radiation when
compared with radiation therapy alone in unresectable
LAPC [40]. Subsequently, gemcitabine-based chemoradia-
tion was evaluated and established as an acceptable treat-
ment option for LAPC, based on the results of the Eastern
Cooperative Oncology Group (ECOG)-4201 trial [41] and
the Taipei trial [42]. Chemotherapy alone is another
management strategy in the neoadjuvant treatment of
LAPC. Combination chemotherapy regimens consisting
of gemcitabine backbone have failed to demonstrate sur-
vival advantage over single agent gemcitabine [43-45].
Non-gemcitabine-based regimens such as FOLFIRINOX
and FOLFOX have also been explored in the neoadjuvant
treatment of LAPC [46-50]. Yet another approach in the
management of LAPC is chemotherapy followed by che-
moradiotherapy prior to surgery. Such strategy has been
looked at in retrospective series with encouraging results,
but prospective phase II/III studies are needed before it
can be incorporated into standard oncologic practice
[50-52]. The four-arm phase III CONKO-7 trial will evalu-
ate the efficacy of neoadjuvant chemotherapy plus chemo-
radiation vs. chemotherapy alone in an estimated 830
unresectable LAPC patients (NCT01827553). The chemo-
therapy options in this trial include either FOLFIRINOX
or gemcitabine. A similar phase III trial in LAPC patients
to evaluate neoadjuvant modified FOLFIRINOX followed
by chemoradiation (with 5-FU as the radiosensitizer) is
planned by the investigators from the Stanford University
(NCT01926197).
Metastatic disease
Approximately 50%–60% of PDAC patients present with
metastatic disease at the time of initial diagnosis [1], and
the standard treatment option for these patients is
chemotherapy. In 1997, gemcitabine monotherapy was
established as the standard of care for metastatic disease.
In this pivotal trial, single agent gemcitabine (1,000 mg/m2
weekly × 7 followed by 1 week of rest, then weekly × 3 every
4 weeks thereafter; n = 63) was compared with weekly
bolus 5-FU (600 mg/m2; n = 63), and a modest survival
benefit was demonstrated in the gemcitabine group (5.6
vs. 4.4 months; P = 0.0025) [53]. The primary efficacy
measure was clinical benefit response (CBR), which wasa composite of measurements of pain, Karnofsky Per-
formance Status (KPS), and weight. The CBR was expe-
rienced by 23.8% of the gemcitabine-treated patients
compared with 4.8% of 5-FU-treated patients (P = 0.0022).
Despite the marginal improvement in 1-year survival,
gemcitabine replaced 5-FU and was approved by the US
Food and Drug Administration (FDA) as a standard treat-
ment option for the treatment of metastatic pancreatic
cancer largely based upon its efficacy in improving the
disease-related symptoms [53]. Thereafter, gemcitabine
continued as the chemotherapeutic standard of care in the
management of patients with metastatic pancreatic cancer
for a long time.
Erlotinib, an epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI), is the only biologic agent
that has been approved for the treatment of advanced
pancreatic cancer (APC). In the phase III PA.3 trial that
randomized 569 patients with locally advanced and
metastatic PDAC, the addition of erlotinib to gemcita-
bine resulted in a statistically significant improvement in
median OS of approximately 10 days (6.24 months vs.
5.91 months; hazard ratio [HR] 0.82; P = 0.038) [54].
Despite the clinically insignificant benefit, the combin-
ation of gemcitabine plus erlotinib received the FDA ap-
proval in November 2005 due to a lack of more effective
treatment options for this devastating disease at the
time. However, due to the associated side effects and an
exceedingly small clinical benefit, the use of this regimen
in routine oncologic practice has remained virtually
non-existent.
In recent years, the evidence has shifted from using
single agent gemcitabine to combination regimens for
front-line treatment of metastatic pancreatic cancer.
FOLFIRINOX and gemcitabine plus nab-paclitaxel have
now been established as the two standard combination
chemotherapy options for metastatic disease. In the ran-
domized phase III PRODIGE 4/ACCORD 11 trial that
consisted of 342 metastatic PDAC patients, FOLFIRI-
NOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, LV
400 mg/m2, and 5-FU 400 mg/m2 given as a bolus
followed by 2,400 mg/m2 given as a 46-hour continuous
infusion every 2 weeks) when compared with gemcita-
bine alone (1,000 mg/m2 weekly for 7 of 8 weeks and
then weekly for 3 of 4 weeks) demonstrated a signifi-
cantly better median OS (11.1 vs. 6.8 months; HR 0.57;
95% confidence interval [CI] 0.45 to 0.73; P < 0.001), PFS
(6.4 months vs. 3.3 months; HR 0.47; 95% CI 0.37 to
0.59; P < 0.001), and objective response rate (ORR; 31.6%
vs. 9.4%; P < 0.001) [55]. Based on the statistically signifi-
cant and clinically meaningful improvement in the sur-
vival, FOLFIRINOX was approved for the first-line
treatment of metastatic PDAC. This improvement in OS
with FOLFIRINOX is, however, associated with significant
toxicity (febrile neutropenia, thrombocytopenia, peripheral
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regimen is only indicated for patients with good perform-
ance status. To improve the tolerability of FOLFIRI-
NOX, a modified regimen was recently proposed in
which the 5-FU bolus is removed and growth factor
prophylaxis is administered routinely [56].
An important contributor to the chemoresistance of
PDAC is the presence of a dense stroma in the tumor
microenvironment. Nab-paclitaxel is albumin-bound pac-
litaxel that has been developed to diminish the stromal
tissue network. The ‘albumin’ in nab-paclitaxel interacts
with secreted protein acidic and rich in cysteine
(SPARC), a matrix glycoprotein that has a role in tumor
invasion and facilitates the uptake of paclitaxel by the
tumor cells [57]. In a phase I/II trial of 67 patients with
metastatic PDAC, nab-paclitaxel plus gemcitabine com-
bination was associated with an ORR of 48%, median
OS of 12.2 months, and 1-year survival of 48% [58].
Subsequently, in a large phase III MPACT trial, 861
metastatic PDAC patients were randomized to receive
nab-paclitaxel (125 mg/m2) followed by gemcitabine
(1,000 mg/m2) on days 1, 8, and 15 every 4 weeks, vs.
gemcitabine monotherapy (1,000 mg/m2) weekly for 7
of 8 weeks (cycle 1) and then on days 1, 8, and 15 every
4 weeks (cycle 2 onwards) [59]. The combination of
nab-paclitaxel plus gemcitabine significantly improved
the median OS from 6.7 months to 8.5 months (HR
0.72; 95% CI 0.62 to 0.83; P < 0.001), PFS from
3.7 months to 5.5 months (HR 0.69; 95% CI 0.58 to
0.82; P < 0.001) and RR from 7% to 23% (P < 0.001)
when compared with gemcitabine alone. In September
2013, the FDA approved nab-paclitaxel plus gemcita-
bine as a first-line treatment option for metastatic
pancreatic cancer based on the results of this study.
Currently, the choice between the two approved stand-
ard first-line chemotherapy options for metastatic
disease (FOLFIRINOX or gemcitabine/nab-paclitaxel)
is usually guided by the patient’s age, performance sta-
tus, preference of treatment frequency, and toxicity
profiles of the two regimens.
Emerging novel therapeutic targets and treatment
strategies
Currently, a multitude of innovative therapeutic ap-
proaches are being developed to target the known mo-
lecular pathways involved in pancreatic tumorigenesis.
Table 1 provides a list of the selected clinical trials that
are currently recruiting patients to evaluate the safety
and efficacy of novel agents in PDAC.
Source: http://www.clinicaltrials.gov; Accessed on January
01, 2015. NCT National Clinical Trial, EGFR epidermal
growth factor receptor, TKI tyrosine kinase inhibitor,
PTEN Phosphatase and tensin homolog, TGF transform-
ing growth factor receptor, mAb monoclonal antibody,CRM1 chromosome region maintenance 1, DNA deoxy-
ribonucleic acid, BET bromodomain and extra-terminal,
SMAC second mitochondrial-derived activator of cas-
pases, hTERT telomerase reverse transcriptase, CTLA-4
cytotoxic T-lymphocyte-associated protein 4, PBMC per-
ipheral blood mononuclear cell, siRNA small interfering
RNA, LA locally advanced.
RAS/RAF/MEK/ERK signaling pathway
Despite being the most common mutation associated
with PDAC, attempts to target KRAS by inhibiting its
post-translational modification have been unsuccessful
so far. Tipifarnib (R115777) is an inhibitor of farnesyl-
transferase (FTase) which is a dominant enzyme involved
in post-translational modification of RAS [60]. So far, it
has not demonstrated any significant antitumor activity
both as a single agent and in combination with gemcita-
bine [44,61,62].
Attempts are being made to identify downstream targets
(mitogen-activated protein kinase [MAPK], phosphatidyli-
nositide 3-kinase [PI3K]) to block KRAS-dependent sig-
naling pathways. Towards this goal, a number of MEK
inhibitors are currently being evaluated in clinical trials
[63]. Selumetenib (AZD6244) is a selective MEK inhibitor
that was found to have similar efficacy as capecitabine in a
phase II clinical trial that enrolled APC patients after fail-
ing first-line gemcitabine therapy [64]. It is also being
tested in combination with erlotinib in APC patients re-
sistant to gemcitabine (NCT01222689). Based on the en-
couraging results of a phase I clinical trial, trametinib
(another MEK inhibitor) was combined with gemcitabine
in a phase II clinical trial of metastatic pancreatic cancer
patients but failed to demonstrate a clinical benefit [65].
Combinations of other novel MEK inhibitors (pimasertib
[MSC1936369B], refametenib [BAY86-9766]) with gemci-
tabine are currently under evaluation in clinical trials.
It is now known that expression of RAS oncogene up-
regulates basal autophagy, which is required for cancer cell
survival in starvation and in tumorigenesis [66]. Autophagy
is therefore believed to be a significant mechanism for pan-
creatic cancer cell survival. Hydroxychloroquine, an anti-
malarial drug is being evaluated as an autophagy inhibitor
for the treatment of these aggressive cancers.
Epidermal growth factor receptor pathway
ErbB-1 (EGFR) and ErbB-2 (HER2/neu) expression is
found in 90% and 21% of pancreatic cancers, respectively
[67,68]. Therapies targeted against EGFR (both TKIs and
monoclonal antibody [mAb]) in pancreatic cancer have
yielded overall disappointing results so far. As discussed
previously, the phase III PA.3 trial evaluated gemcitabine
in combination with erlotinib in the first-line treatment
of APC and was associated with a clinically insignificant
improvement in median OS when compared with
Table 1 Summary of selected novel agents that are under evaluation in currently actively recruiting clinical trials
Primary modes of action Study agent(s) NCT identifier Phase Disease stage
MEK inhibitor + Bcl-2 inhibitor Trametinib, navitoclax NCT02079740 Ib/II LA, metastatic
MEK inhibitor + ErbB inhibitor PD-0325901, dacomitinib NCT02039336 I/II Metastatic
Trametinib, lapatinib NCT02230553 I/II Metastatic
EGFR TKI Afatinib NCT01728818 II Metastatic
PI3K inhibitor BKM120 NCT01571024 I Metastatic
BYL719 NCT02155088 I LA, metastatic
PI3K inhibitor + MEK inhibitor BYL719, MEK162 NCT01449058 Ib/II Metastatic
AKT inhibitor MK2206 NCT01783171 I LA, metastatic
PTEN inducer AXP107-11 NCT01182246 Ib/II LA, metastatic
Wnt signaling inhibitor OMP-54 F28 NCT02050178 Ib Metastatic
OMP-18R5 NCT02005315 Ib Metastatic
PRI-724 NCT01764477 I LA, metastatic
LGK974 NCT01351103 I LA, metastatic
Glycogen synthase kinase-3 inhibitor LY2090314 NCT01632306 I, II Metastatic
Notch signaling inhibitor MK0752 NCT01098344 I LA, metastatic
PF-03084014 NCT02109445 Ib/II Metastatic
OMP-59R5 NCT01647828 Ib/II Metastatic
OMP-21 M18 NCT01189929 Ib LA, metastatic
Anti-connective tissue growth factor mAb FG-3019 NCT02210559 II LA unresectable
Heparan sulfate mimetic M402 NCT01621243 I/II Metastatic
Hyaluronidase PEGPH20 NCT01839487 II Metastatic
NCT01959139 I/II Metastatic
Hyaluronidase + anti-EGFR mAb PEGPH20, cetuximab NCT02241187 NP Resectable
Oncolytic adenovirus encoding hyaluronidase VCN-01 NCT02045589 I LA, metastatic
Hedgehog inhibitor IPI-926 NCT01383538 I LA, metastatic
GDC-0449 NCT01088815 II Metastatic
LDE-225 NCT01431794 I/II LA
Hypoxia targeting agent TH-302 NCT02047500 I LA, metastatic
TGF-β receptor I inhibitor LY2157299 NCT01373164 Ib/II LA, metastatic
Hypomethylating agent Azacitidine NCT01845805 II Resected
AMP-activated protein kinase (AMPK) activator Metformin NCT01954732 I Localized
Metformin NCT02005419 II Localized
Metformin NCT01666730 II Metastatic
AMPK activator + mTOR inhibitor Metformin, Rapamycin NCT02048384 Ib/II Metastatic
poly (ADP-ribose) polymerase (PARP) inhibitor Veliparib NCT01908478 I LA
Veliparib NCT01489865 I/II Metastatic
Veliparib NCT01585805 II LA, metastatic
Rucaparib (AG-14699) NCT02042378 II LA, metastatic
(BRCA mutant)
Olaparib (AZD2281) NCT02184195 III Metastatic
(BRCA mutant)
Vascular targeting agent ADH-1 NCT01825603 I LA, metastatic
Antiangiogenic combination Tl-118 NCT01509911 II Metastatic
Arginine degrading enzyme ADI-PEG 20 NCT02101580 Ib LA, metastatic
Goel and Sun Journal of Hematology & Oncology  (2015) 8:44 Page 6 of 16
Table 1 Summary of selected novel agents that are under evaluation in currently actively recruiting clinical trials
(Continued)
Aurora A kinase inhibitor Alisertib (MLN8237) NCT01924260,
NCT01677559
I LA, metastatic
CDK inhibitor + AKT inhibitor Dinaciclib, MK2206 NCT01783171 I LA, metastatic
α-ketoglutarate dehydrogenase (KGDH) inhibitor CPI-613 NCT01835041 I Metastatic
CPI-613 NCT01839981 I LA, metastatic
c-Met inhibitor Cabozantinib (XL184) NCT01663272 I LA, metastatic
CRM-1 inhibitor Selinexor (KPT-330) NCT02178436 Ib/II Metastatic
DNA minor groove binder Lurbinectedin NCT02210364 I LA
unresectable
Src inhibitor Dasatinib NCT01652976 II Metastatic
Trk A, B, C inhibitors PLX7486 NCT01804530 I LA, metastatic
IDO inhibitor Indoximod NCT02077881 I/II Metastatic
NLG919 NCT02048709 I Refractory
Chemokine receptor 2 (CCR2) antagonist PF-04136309 NCT01413022 I LA
Anti-tissue factor mAb MORAb-066 NCT01761240 I LA, metastatic
Wee 1 inhibitor MK1775 NCT02037230 I/II LA
unresectable
BET bromodomain inhibitor OTX015 NCT02259114 Ib LA, metastatic
SMAC mimetic LCL161 NCT01934634 I Metastatic
Cancer stemness inhibitor BBI608 NCT02231723 Ib Metastatic
Janus Kinase (JAK) inhibitor Ruxolitinib NCT01822756 I Metastatic
Ruxolitinib NCT02117479,
NCT02119663
III Metastatic
INCB039110 NCT01858883 Ib Metastatic
Momelotinib NCT02101021 II Metastatic
Autophagy inhibitor Hydroxychloroquine NCT01506973 I/II Metastatic
Hydroxychloroquine NCT01978184 II Resectable
Hydroxychloroquine NCT01494155 II Resectable
Cancer vaccine GVAX NCT01088789 II Localized
Poly ICLC and dendritic cells NCT01677962 0 LA unresectable
Autologous tumor-derived HSP gp96 NCT02133079 I/II Resected
GVAX/CRS-207 NCT02004262 II Metastatic
Algenpantucel-L NCT01836432 III LA
hTERT DNA cancer vaccine INO-1400 NCT02327468 I Non-metastatic
CTLA-4 inhibitor Ipilimumab NCT01473940 Ib LA, metastatic
Anti-PD-1 mAb CT-011 NCT01313416 II Resected
Vaccine + CTLA-4 inhibitor GVAX, ipilimumab NCT01896869 II Metastatic
Vaccine + anti-PD-1 mAb GVAX/CRS-207, nivolumab NCT02243371 II Metastatic
CTLA-4 inhibitor + anti-PD-1 mAb Ipilimumab, nivolumab NCT01928394 I/II LA, metastatic
Anti-CPAA mAb NPC-1C NCT01834235 I/II LA, metastatic
NPC-1C NCT01040000 II LA, metastatic
Anti-MUC1 mAb BTH1704 NCT02132403 I LA, metastatic
Anti-CEA BiTE mAb MEDI-565 NCT01284231 I Refractory
Anti-CA-125 mAb Oregovomab NCT01959672 II Non-metastatic
Pegylated recombinant human IL-10 AM0010 NCT02009449 I Metastatic
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Table 1 Summary of selected novel agents that are under evaluation in currently actively recruiting clinical trials
(Continued)
IL-1 receptor antagonist Anakinra NCT02021422 I Metastatic
RAS specific immunotherapy TG01 NCT02261714 I/II Resected
Radioimmunotherapy 90Y-clivatuzumab tetraxetan (IMMU-
107)
NCT01956812 III Metastatic
Activated T-cells EGFRBi armed ATC infusions NCT01420874 I Metastatic
Dendritic cell/cytokine-induced killer cells DC-CIK NCT01781520 I/II LA, metastatic
siRNA-transfected PBMC APN401 NCT02166255 I LA, metastatic
Autologous CAR T-cells RNA mesothelin re-directed CAR T-
cells
NCT01897415 I Metastatic
Anti-mesothelin gene engineered
lymphocytes
NCT01583686 I/II Metastatic
Autologous natural killer T-cells NKT cells NCT01801852 I Refractory
Activated dendritic cells DCVax-Direct NCT01882946 I/II LA, metastatic
Autologous tumor infiltrating lymphocytes +
interleukin
TIL, IL-2 NCT01174121 II Metastatic
Antiguanylyl cyclase C antibody-drug
conjugate (ADC)
MLN0264 NCT02202785 II LA, metastatic
Micellar nanoparticle-encapsulated cisplatin NC-6004 NCT02043288 III LA or
metastatic
Alkylating agent Glufosfamide NCT01954992 III Metastatic
Goel and Sun Journal of Hematology & Oncology  (2015) 8:44 Page 8 of 16gemcitabine alone [54]. In another phase II study of
gemcitabine-refractory APC patients, a combination of
erlotinib and capecitabine was associated with only 10%
radiological response and a median OS of 6.5 months
[69]. The combination of cetuximab and gemcitabine
has also been evaluated in the treatment of APC patients
[70,71]. The initial phase II study demonstrated stable
disease (SD) in 63% and partial response (PR) in 12% of
the EGFR-expressing APC patients that were treated
with cetuximab plus gemcitabine combination [70]. In a
subsequent phase III study (Southwest Oncology Group
[SWOG]-directed intergroup trial S0205), this combin-
ation was not associated with any survival benefit when
compared with the single agent gemcitabine (6.3 months
vs. 5.9 months; HR 1.06; 95% CI 0.91 to 1.23; P = 0.23)
[71]. A randomized phase II study of panitumumab, er-
lotinib, and gemcitabine combination suggested a trend
towards OS benefit when compared with erlotinib plus
gemcitabine [72]. However, this three-drug combination
with dual inhibition of the EGFR pathway was associated
with significant toxicities leading to early termination of
the study. Anti-HER2 agent trastuzumab has been com-
bined with gemcitabine in a phase II study that included
metastatic pancreatic cancer patients with 2+ (88% pa-
tients) or 3+ (12% patients) HER2/neu overexpression
by immunohistochemistry [73]. The response rate of this
combination was very similar to gemcitabine alone.
One of the probable explanations for the lack of a
meaningful benefit from anti-EGFR TKIs in pancreatic
cancer could be the development of acquired resistanceto these agents, which is a mechanism well studied in
lung cancer [74]. Clinical trials evaluating newer EGFR
TKIs such as afatinib (NCT01728818) and dacomitinib
(NCT02039336) in pancreatic cancer are currently
underway.
Anti-angiogenesis
Targeting vascular endothelial growth factor (VEGF)
pathway has shown promising results in the treatment
of many solid cancers. However, anti-VEGF therapies
have been ineffective clinically in treating patients with
PDAC. The phase III Cancer and Leukemia Group B
(CALGB) 80303 trial randomized 602 patients with APC
to receive gemcitabine with or without bevacizumab in
the first-line setting [75]. The addition of bevacizumab
to gemcitabine was associated with increased toxicity
and without any improvement in survival (5.8 months
vs. 5.9 months; P = 0.95). In another large, randomized
phase III trial (AVITA), 607 metastatic pancreatic cancer
patients were randomized to receive gemcitabine plus
erlotinib with either bevacizumab or placebo [76]. The
bevacizumab arm was associated with statistically signifi-
cant PFS advantage (4.6 months vs. 3.6 months; HR
0.73; P = 0.0002) but a non-significant improvement in
median OS (7.1 months vs. 6 months; HR 0.89; P =
0.2087). Axitinib is a selective oral inhibitor of VEGF
receptor-1, -2, and -3 that has been combined with gem-
citabine in a phase II clinical trial of APC patients and
showed a statistically non-significant gain in OS [77]. A
subsequent phase III study that randomized 632 APC
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was terminated early due to the lack of survival benefit
(8.5 months vs. 8.3 months; HR 1.014; P = 0.5436) at the
time of planned interim analysis [78]. Ziv-Aflibercept is
an anti-VEGF recombinant fusion protein that has also
been combined with gemcitabine in a phase III trial for
the treatment of metastatic pancreatic cancer patients
[79]. However, this trial was terminated early as well due
to the lack of efficacy at the time of planned interim
analysis. Sorafenib and masitinib are oral multikinase in-
hibitors with antiangiogenic properties. In the phase III
BAYPAN trial, addition of sorafenib to gemcitabine did
not improve PFS in APC patients [80]. The phase III
study of gemcitabine plus masitinib also did not result in
improvement of OS in patients with unresectable pan-
creatic cancer [81].
Insulin-like growth factor-1 receptor
Insulin-like growth factor (IGF)-1 receptor is highly
expressed in PDAC and participates in downstream sig-
naling pathways that are involved in cancer cell survival
and proliferation. Several mAbs against IGF-1 receptor
(cixutumumab, ganitumab, dalotuzumab) are currently
being tested in clinical trials. Ganitumab (AMG 479)
was studied in combination with gemcitabine in a phase
II trial of metastatic pancreatic cancer patients and
showed a slight improvement in 6-month survival rate
when compared with gemcitabine plus placebo (57% vs.
50%) [82]. However, the phase III GAMMA trial of gani-
tumab plus gemcitabine combination was terminated
early due to lack of efficacy at the preplanned interim
analysis. In another phase II trial that evaluated cixutu-
mumab plus gemcitabine and erlotinib in metastatic
pancreatic cancer patients, the three-drug combination
did not improve the PFS or OS when compared with
gemcitabine plus erlotinib [83].
PI3K/AKT/mTOR pathway
This is one of the major downstream effector pathways
of KRAS gene that is being evaluated as a potential tar-
get for pancreatic cancer treatment [84]. Rigosertib is a
small molecular inhibitor of PI3K that was combined
with gemcitabine in a phase II/III clinical trial
(ONTRAC trial). The study was terminated early due to
lack of demonstration of benefit at the time of interim
analysis. Buparlisib (BKM120) is another PI3K inhibitor
being evaluated in combination with mFOLFOX6 regi-
men in a study of advanced stage solid tumors including
pancreatic cancer (NCT01571024). MK2206 is an AKT
inhibitor currently under clinical evaluation in patients
with pancreatic cancer (NCT01783171, NCT01658943).
Archexin (RX-0201) is another AKT inhibitor that was
evaluated in combination with gemcitabine in a phase II
study (NCT01028495). BEZ235 is a combined inhibitorof PI3K and mTOR. A phase I study evaluating the ac-
tivity of BEZ235 plus a MEK inhibitor (MEK162) in ad-
vanced solid tumor patients (including pancreatic
cancer) with KRAS, NRAS and/or BRAF mutations has re-
cently completed (NCT01337765). Everolimus (RAD001)
is a mTOR inhibitor that was associated with a PFS of
1.8 months and OS of 4.5 months in a phase II study con-
sisting of 33 gemcitabine-refractory, metastatic pancreatic
cancer patients [85]. It is also being evaluated as a part of
combination regimens with other agents in ongoing clin-
ical trials.
Wnt/β-catenin pathway
Wnt signals are transduced through the frizzled receptor
and lipoprotein-related protein to the β-catenin signaling
cascade. There is evidence to suggest that Wnt pathway
plays a role in pancreatic cancer formation via involve-
ment in pancreatic cancer stem cells (CSCs) [86,87].
Phase I trials using mAbs (OMP-54 F28, OMP-18R5)
against frizzled receptors to inhibit Wnt signaling in PDAC
are currently ongoing (NCT02050178, NCT02005315).
Notch signaling pathway
Notch signaling has been shown to be upregulated in
many human cancers including PDACs [88,89]. It medi-
ates pancreatic CSC function and contributes to chemo-
therapy resistance, tumor recurrence, and metastases.
Gamma secretase is an enzyme that causes proteolytic
cleavage and release of the intracellular domain of the
Notch, leading to activation of the Notch signaling path-
way. In preclinical models, inhibition of Notch pathways
with a gamma-secretase inhibitor (GSI) in combination
with gemcitabine showed enhanced antitumor activity
[90]. A phase II study evaluating an oral GSI (RO4929097)
in pretreated metastatic pancreatic cancer patients was
recently completed (NCT01232829). MK0752 is an-
other GSI being tested in combination with gemcita-
bine for first-line treatment of stage III and IV PDAC
patients (NCT01098344). Tarextumab (anti-Notch2/3
mAb, OMP-59R5) and demcizumab (anti-DLL4 mAb,
OMP-21 M18) also inhibit Notch signaling and are be-
ing evaluated in clinical trials. ALPINE trial is studying
the combination of tarextumab with nab-paclitaxel and
gemcitabine (NCT01647828).
Targeting desmoplastic tumor microenvironment
The desmoplastic stroma in the tumor microenviron-
ment is now regarded as a key component of pancreatic
cancer biology which not only acts as a physical barrier
to effective drug delivery inside the tumor but also facili-
tates tumor growth and promotes metastases. Strategies
aimed at targeting the stromal compartment may en-
hance the delivery of chemotherapeutic agents to the
tumor cells leading to improved efficacy. The most
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hyaluronic acid, and SPARC.
SHH pathway is an important signaling system that
can activate the characteristic desmoplastic reaction
present in the microenvironment of pancreatic tumors
[22]. Sustained activation of this pathway enhances
tumor growth during pancreatic oncogenesis [91]. Sev-
eral clinical trials have been initiated to investigate the
activity of SHH inhibitors in patients with PDAC. Vis-
modegib (GDC-0449) is a SHH inhibitor under clinical
evaluation in combination with gemcitabine and nab-
paclitaxel (NCT01088815). Saridegib (IPI-926) is another
agent targeting the SHH pathway that was combined
with gemcitabine in a phase II study of APC, but the
trial was prematurely terminated since the combination
was associated with a shorter survival than gemcitabine
alone (NCT01130142). A study combining the SHH in-
hibitor sonidegib (LDE225) with FOLFIRINOX in un-
treated APC patients is ongoing (NCT01485744).
Hyaluronan is a glycosaminoglycan present in the
extracellular matrix of PDAC, and high levels within the
tumor are usually associated with a poor prognosis.
Pegylated human recombinant PH20 hyaluronidase
(PEGPH20) degrades hyaluronan and has been shown to
decrease the hyaluronic acid content in a genetically-
engineered PDAC mouse model, allowing for re-
expansion of the PDAC blood vessels and enhanced
intratumoral delivery of chemotherapeutic agents which
leads to decreased tumor growth [92]. Clinically, the
combination of PEGPH20 plus gemcitabine has shown
promising activity in a phase Ib study of metastatic pan-
creatic cancer patients [93], and a phase II study of this
combination is ongoing (NCT01453153). Another phase
Ib/II study of PEGPH20 plus modified FOLFIRINOX
combination in metastatic pancreatic cancer patients is
currently under clinical evaluation (NCT01959139).
SPARC (osteonectin) is an extracellular matrix protein
that plays a role in collagen turnover in the dense
stroma. It is associated with invasion and metastasis in
PDAC, and elevated levels are associated with poor
prognosis. Nab-paclitaxel is albumin-bound paclitaxel
that increases tumor accumulation of paclitaxel through
binding of albumin to the stroma rich in overexpression
of SPARC. As described previously, the efficacy of nab-
paclitaxel plus gemcitabine combination in the first-line
treatment of metastatic pancreatic cancer was demon-
strated in the phase III MPACT trial which ultimately
led to its FDA approval [59].
Some of the other novel strategies aimed at targeting
the desmoplastic stroma within the pancreatic tumor in-
clude the use of matrix metalloproteinase (MMP) inhibi-
tors, heparin derivatives, and hypoxia targeting agents.
MMP inhibitors have been tried for the treatment of PDAC
without much success to date. Marimastat (BB-2516) is abroad spectrum MMP inhibitor that was combined
with gemcitabine in the treatment of APC but did not
show any demonstrable clinical benefit [94]. Tanoma-
stat (BAY12-9566) is another biphenyl MMP inhibitor
with antiangiogenic and antimetastatic properties that
was compared with gemcitabine for the treatment of
APC patients and was found to be inferior to gemcita-
bine [95]. Heparin-derivative agents such as 2-0, 3-0
desulfated heparin (ODSH) and necuparanib (M402)
are currently being studied in combination with gemcita-
bine and nab-paclitaxel for treatment of patients with meta-
static pancreatic cancer (NCT01461915, NCT01621243). It
is now well established the pancreatic tumor microenviron-
ment is characterized by hypoxia. Consequently, hypoxia-
targeting agents are being developed to evaluate this novel
therapeutic strategy. TH-302 is a hypoxia-activated prodrug
that is activated into a potent DNA-alkylating agent,
bromo-isophosphoramide mustard selectively under hyp-
oxic conditions. A recent phase II study of TH-302 plus
gemcitabine showed a significant improvement in pri-
mary end point of PFS when compared with gemcita-
bine alone (5.6 months vs. 3.6 months; HR 0.61; 95% CI
0.43 to 0.87; P = 0.005) [96]. A phase III trial of this
combination is currently in progress (MAESTRO study;
NCT01746979).
TGF-β signaling pathway
TGF-β participates in stimulating stromal reaction, inva-
sion, metastases, and angiogenesis in PDAC [97]. Exam-
ples of novel agents that target TGF-β signaling include
trabedersen (AP-12009) and galunisertib (LY2157299).
Trabedersen is a specific inhibitor of TGF-β2 that has
demonstrated good safety and encouraging survival re-
sults in the phase I/II clinical study [98]. Galunisertib is
being evaluated in combination with gemcitabine for the
treatment of patients with APC in an ongoing phase Ib/
II clinical trial (NCT01373164).
Epigenetic modification
Epigenetic changes such as histone deacetylation (HDAC)
and DNA methylation (cytosine methylation within CG
dinucleotides) can result in inactivation of the tumor sup-
pressor genes leading to tumor growth and progression.
Vorinostat is a HDAC inhibitor being tested in a phase I/
II study of LAPC patients in combination with capecita-
bine and radiotherapy (NCT00948688). 5-Azacytidine is a
cytosine analog that inhibits DNA methyltransferase, and
a phase I study of its combination with gemcitabine in
APC patients was recently terminated (NCT01167816).
Adenosine monophosphate-activated protein kinase
pathway
The oral anti-diabetic drug metformin is an activator of ad-
enosine monophosphate-activated protein kinase (AMPK)
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protein-coupled receptors (GPCR) signaling in pancreatic
cancer cells, via inhibition of mTOR and suppression of its
downstream effectors [99]. In xenograft mice models, met-
formin has been shown to inhibit pancreatic cancer growth
[99]. Clinically, the available data surrounding the benefit
of metformin in pancreatic cancer is conflicting and is
mostly derived from retrospective studies. In a hospital-
based case-control study, metformin was shown to de-
crease the risk of developing pancreatic cancer among
diabetics [100]. In another retrospective analysis, met-
formin use was associated with an improvement in sur-
vival for the PDAC patients with diabetes [101]. In
contrast, a more recent study from the UK failed to
demonstrate a survival benefit from metformin use in
PDAC patients [102]. There are multiple ongoing phase
I and phase II trials that are evaluating the efficacy of
metformin in PDAC. A phase I study of metformin plus
erlotinib and gemcitabine in patients with APC has re-
cently completed accrual (NCT01210911).
Synthetic lethality
The DNA double-strand breaks are repaired by a
process of homologous recombination that is mediated
via BRCA1 and BRCA2 proteins. Mutations in BRCA
render this repair mechanism dysfunctional and are
known to occur in both sporadic and familial cases of
pancreatic cancer. Poly (ADP-ribose) polymerase (PARP)
is another critical enzyme that mediates repair of DNA
single-strand breaks. PARP pathway assumes the major
role for DNA repair when BRCA mutation occurs. Con-
sequently, inhibition of the PARP pathway results in
‘synthetic lethality’ via inhibition of DNA repair in
BRCA-deficient tumor cells. A phase II study of veli-
parib alone or in combination with gemcitabine plus cis-
platin for locally advanced and metastatic, BRCA 1–2,
and PALB2-mutated pancreatic cancer patients is on-
going (NCT01585805). Other PARP inhibitors that are
being evaluated in pancreatic cancer clinical trials in-
clude rucaparib (AG-14699; NCT02042378) and ola-
parib (AZD2281; NCT00515866).
Immunotherapy-based approaches
Despite significant efforts, no immunotherapeutic strat-
egy against pancreatic cancer has demonstrated clinical
benefit in a randomized phase III trial till date. This has
been attributed to the immunologically quiescent micro-
environment of pancreatic cancer. Currently, several ap-
proaches aimed at stimulating the host immune system
against the pancreatic cancer tumor cells are under
evaluation.
GI-4000, a form of RAS-specific immunotherapy, is
heat-killed recombinant Saccharomyces cerevisiae yeast
that expresses mutant RAS peptides [103]. A phase IItrial of GI-4000 plus adjuvant gemcitabine is ongoing
(NCT00300950). Reovirus is a tumor-targeted replication-
competent virus with specificity for RAS-activated cells
[104]. It is being combined with chemotherapy for the
treatment of APC patients in two phase II clinical trials
(NCT00998322, NCT01280058).
Developing vaccines against tumor antigens is an-
other potential immunotherapeutic strategy to treat
pancreatic cancer. Several antigens have been explored
as potential targets for vaccine-based treatment in pan-
creatic cancer including carcinoembryonic antigen
(CEA) [105], MUC1 [106,107], and heat shock proteins
(HSP) [108]. Algenpantucel-L immunotherapy is a
whole-cell allogeneic pancreatic cancer vaccine com-
posed of two irradiated human pancreatic cell lines that
have been genetically modified to overexpress murine
alpha(1,3)-galactosyltransferase, resulting in expression
of alpha-galactosyl (Alpha-Gal) epitopes on membrane
glycoproteins and glycolipids. Since human cells do not
express these epitopes, an immediate hyperacute rejec-
tion response ensues leading to the development of
strong T-cell mediated antitumor immunity. This im-
munotherapeutic agent has demonstrated encouraging
activity when combined with radiation and 5-FU plus
gemcitabine in a phase II adjuvant trial of resected
PDAC patients [109]. The phase III adjuvant trial that
compares gemcitabine with or without algenpantucel-L,
followed by chemoradiation has also completed recently
(NCT01072981). Another phase III neoadjuvant trial is
evaluating FOLFIRINOX with or without algenpantucel-L,
followed by chemoradiation in borderline-resectable and
unresectable LAPC patients (NCT01836432). GV1001 is a
telomerase peptide vaccine shown to prolong survival
when combined with granulocyte-macrophage colony-
stimulating factor (GM-CSF) in a phase I/II study of unre-
sectable LAPC patients [110]. However, the phase III study
comparing GV1001 and gemcitabine in sequential combin-
ation, vs. gemcitabine monotherapy in advanced unresect-
able pancreatic cancer was terminated early due to lack of
survival benefit in the GV1001 arm (NCT00358566).
G17D (Gastrimmune) is an antigastrin-17 immunogen that
was evaluated in a randomized, multicenter, placebo-
controlled study of APC patients and showed a non-
significant improvement in OS when compared to pla-
cebo [111]. Another potential therapeutic strategy that
has been explored is combining two vaccines (GVAX
plus CRS-207) with the hope to achieve an enhanced
efficacy. GVAX is composed of pancreatic cancer cells
that have been genetically modified to secrete GM-CSF
and can induce T-cell responses. CRS-207 is a live-
attenuated Listeria-based vaccine that can induce lister-
iolysin O and mesothelin-specific T-cell responses. The
combination of GVAX plus CRS-207 is being evaluated
in a phase IIb clinical trial (ECLIPSE) that consists of
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(NCT02004262).
Prostate stem cell antigen (PSCA) is a
glycosylphosphatidylinositol-linked cell surface anti-
gen expressed in pancreatic cancers. AGS-1C4D4 is a
fully human IgG1 mAb against PSCA that has been
combined with gemcitabine for the treatment of meta-
static pancreatic cancer patients and has shown en-
couraging results [112].
It is now established that CD40 activation can reverse
immune suppression and drive antitumor T-cell re-
sponses. Utilizing this concept, agonist CD40 antibody
has been used in combination with gemcitabine in a
phase I study to shrink PDAC by stimulating tumor
macrophages against pancreatic cancer stroma [113].
Immunoinhibitory checkpoint pathways (cytotoxic T
lymphocyte-associated protein-4 [CTLA-4]/B7, programmed
cell death-1 [PD-1]/programmed cell death ligand-1
[PD-L1]) are emerging as interesting immunotherapeu-
tic targets for the treatment of cancer. Single agent ipi-
limumab was evaluated in a phase II trial of APC and
failed to demonstrate an appreciable antitumor activity
[114]. The combination of ipilimumab with gemcitabine is
currently under phase I evaluation (NCT01473940).
Radioimmunotherapy with 90Y-clivatuzumab tetra-
xetan (radioimmunoconjugate comprised of the hu-
manized mAb HuPAM4 that is radiolabeled with
yttrium-90) is another potential therapeutic strategy that
is being evaluated in clinical trials. The combination of
90Y-clivatuzumab tetraxetan with low-dose gemcitabine
demonstrated a median OS of 7.7 months in a phase I
study of untreated APC patients [115]. The phase III study
(PANCRIT-1) of this combination in pretreated metastatic
pancreatic cancer patients is ongoing (NCT01956812).
An additional therapeutic strategy is adoptive cell transfer
(ACT) approach which utilizes introduction of engineered
T-cells with chimeric antigen receptors (CARs) to specific-
ally recognize a tumor antigen of interest. This personalized
immunotherapy approach is still under preclinical stages of
development in the field of pancreatic cancer [116].
Novel cytotoxic agents
PEP02 (MM-398) is a novel nanoparticle liposomal
formulation of irinotecan. In a phase II study of
gemcitabine-refractory metastatic PDAC patients, treat-
ment with single agent PEP02 was associated with a me-
dian PFS and OS of 9 weeks and 21.6 weeks, respectively
[117]. A phase III trial (NAPOLI 1) is evaluating the com-
bination of PEP02 with 5-FU in metastatic pancreatic can-
cer patients who have failed prior gemcitabine-based
therapy (NCT01494506).
S-1 is a fourth-generation oral fluoropyrimidine that
contains tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-
dihydropyrimidine (CHDP), and potassium oxonate (Oxo).It has been evaluated in the treatment of both resect-
able and advanced pancreatic cancer with encouraging
results. In a phase II Japanese study (PC-01), 116 pa-
tients with unresectable APC were randomized to re-
ceive gemcitabine plus S-1 vs. gemcitabine alone [118].
There was significant improvement in the ORR (28.3%
vs. 6.8%; P = 0.005) and median OS (13.7 months vs.
8.0 months; P = 0.035) in the S-1 arm. Japan Adjuvant
Study Group of Pancreatic Cancer (JASPAC-01) is a
phase III non-inferiority trial that compared S-1 with
gemcitabine as adjuvant chemotherapy for patients with
curatively resected pancreatic cancer [119]. The interim
analysis showed that S-1 was non-inferior to gemcita-
bine (OS at 2 years was 70% vs. 53%; HR 0.56; 95% CI
0.42 to 0.74; P < 0.0001 for non-inferiority) [120]. Based
on the results of this study, the authors proposed that
S-1 should be considered as a new standard treatment
for patient with resected pancreatic cancer.
Identification of biomarkers
Development of more efficacious approaches for pancre-
atic cancer treatment would require identification of bio-
markers that can predict the response and toxicity to
various therapeutic agents. Research efforts geared to-
wards this objective are underway.
The human equilibrative nucleoside transporter-1
(hENT1) plays an important role in the uptake of gemci-
tabine in cells and has been evaluated as a potential pre-
dictive biomarker of gemcitabine response. In a study
that evaluated the expression pattern of genes involved
in gemcitabine activity in 102 pancreatic tumor speci-
mens, it was found that low hENT-1 expression levels
were associated with a poorer prognosis [121]. However,
in the pivotal phase II Low hENT1 and Adenocarcinoma
of the Pancreas (LEAP) study, the hENT1 status was
shown to have no clinical utility for predicting gemcita-
bine sensitivity [122]. Some additional potential bio-
markers that have been evaluated in pancreatic cancer
treatment include deoxycytidine kinase (dCK), ribonucleo-
side reductase-M1 (RRM1), and -M2 (RRM2) [123,124],
KRAS status, SPARC staining [58], IGF-1R expression,
and rs9582036 single nucleotide polymorphism (SNP) in
the VEGF receptor-1 region [125]. Recently, pharmacoge-
nomic profiling of circulating tumor and invasive cells
(CTICs) isolated from patients with PDAC was evaluated
as a predictor of tumor response, progression, and resist-
ance [126].
Future directions and conclusion
The therapeutic advances in the field of pancreatic can-
cer have been painstakingly slow. Although we have seen
a few breakthroughs in therapy for advanced disease in
the recent years, the overall progress made in the field
of pancreatic cancer has been relatively small in
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noted that the majority of pancreatic cancer clinical tri-
als over the past 5 years have failed to demonstrate any
significant clinical benefit. A substantial fraction of these
studies evaluated drug combinations using gemcitabine
as the chemotherapy backbone. This should make us
think that maybe it is time to move away from
gemcitabine-based combinations and focus attention on
developing innovative strategies to attack the pancreatic
cancer oncogenesis. Selecting drug combinations with
novel agents that target not only the primary tumor but
also the surrounding stroma might be one such ap-
proach. Since our ability to safely combine drugs will be
enhanced if the drug selection is based on biomarkers,
we would also need prospective studies to validate po-
tential biomarkers in well-defined patient populations in
order to maximize the clinical efficacy while minimizing
the toxicity of the therapeutic agents.
It is now well established that pancreatic cancer is a
heterogeneous and a genetically diverse disease that re-
sults from successive accumulation of mutations over a
long period of time, and these mutations affect multiple
molecular pathways involved in pancreatic tumorigen-
esis. The presence of desmoplastic reaction in the tumor
microenvironment and its role in pancreatic cancer initi-
ation, invasion, and metastases is also being recognized.
Consequently, multiple potential therapeutic approaches
against pancreatic cancer are being developed and evalu-
ated in several ongoing preclinical and clinical trials. We
are hopeful that at least some of these novel strategies
will demonstrate clinically meaningful benefit in future
phase III studies and add to our armamentarium for
treating this lethal malignancy.
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